showme
Prominent proteins in cancer
This is the list of significantly mutated genes (SMGs) and other proteins significantly involved in edgetic perturbations in KIRC.
Perturbation typeGeneCitationCancer typeGene-disease relation
Top gainsGRAMD2B GRAMD3) (Isoform switch)20502531: 17699851KIRCDifferentially expressed in KIRC patients compared to expression profiles in heathy controls
Top gainsGRAMD1C (Isoform switch)14641932KIRCDifferentially expressed in KIRC patients compared to expression profiles in heathy controls
Top lossesVSIG8 (Isoform switch)21253009KIRCDifferentially expressed in KIRP patients compared to expression profiles in noncancerous kidney cortical samples
Top lossesSHC1 (Isoform switch)27993167KIRCHighly expressed in better outcome KIRC cases
Top cancer-specific gainsCDC25C14641932KIRCDifferentially expressed in tumor samples compared to normal samples.
Top cancer-specific gainsCDC4520502531KIRCDifferentially expressed in tumor samples compared to normal samples.
Top cancer-specific gainsCDKN2A23792563KIRCDeletion associated with KIRC.
Top cancer-specific gainsEME120502531KIRCDifferentially expressed in tumor samples compared to normal samples.
Top cancer-specific gainsCENPA28553932KIRCDifferentially expressed in tumor samples in mouse model.
Top cancer-specific gainsFASLG20572163RCCPolymorphism associated with risk of RCC.
Top cancer-specific gainsKIF1414641932:19123481KIRC:KIRPDifferentially expressed in tumor samples in KIRC and KIRP.
Top cancer-specific gainsLGALS9C25716202KIRCGalectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma.
Top cancer-specific gainsMCM1026859141KIRCDown-regulated in KIRC and target for miR-146a-5p.
Top cancer-specific gainsNEIL314641932KIRCDifferentially expressed in tumor samples compared to normal samples.
Top cancer-specific gainsSGO114641932KIRCDifferentially expressed in tumor samples compared to normal samples.
Top cancer-specific gainsMLC127633759KIRCThe activation of RhoA/ROCK/MLC signaling by honokiol suppresses the migration of highly metastatic RCC.
Top lossesASB1414641932KIRCDifferentially expressed in tumor samples compared to normal samples.
Top lossesBIK16322756KIRCThe conditional restoration of Nbk/Bik expression led to apoptotic death of RCC but not of nonmalignant renal epithelia.
Top lossesBNIPL14641932KIRCDifferentially expressed in tumor samples compared to normal samples.
Top lossesCLNK14641932KIRCDifferentially expressed in tumor samples compared to normal samples.
Top lossesESRRB14641932KIRCDifferentially expressed in tumor samples compared to normal samples.
Top lossesFBN326807193CRCCMutation in FBN3 associated with CRCC.
Top lossesFOXA314641932KIRCDifferentially expressed in tumor samples compared to normal samples.
Top lossesGRIK214641932KIRCDifferentially expressed in tumor samples compared to normal samples.
Top lossesHAP114641932KIRCDifferentially expressed in tumor samples compared to normal samples.
Top lossesOLFM424649153RCCOLFM4 was not detected in the 86 RCC cases. OLFM4 is likely to have tumor suppressive properties in RCC.
Top lossesRAB40A14641932KIRCDifferentially expressed in tumor samples compared to normal samples.
Top lossesSOX3028029648KIRPOverexpressed in KIRP black vs. white KIRP patients with a fold change ≥ 2.
Top lossesTCAP14641932KIRCDifferentially expressed in tumor samples compared to normal samples.
Top lossesUSP4414641932KIRCDifferentially expressed in tumor samples compared to normal samples.
Top cancer-specific lossesBIK16322756KIRCThe conditional restoration of Nbk/Bik expression led to apoptotic death of RCC but not of nonmalignant renal epithelia.
SMGs within edgetic gains or lossesELOC27530247KIRCELOC missense mutations associated with KIRC.
SMGs within edgetic gains or lossesHIF1A15350301KIRCHIF1A polymorphism associated with KIRC.
SMGs within edgetic gains or lossesKAT714641932KIRCDifferentially expressed in tumor samples compared to normal samples.
SMGs within edgetic gains or lossesMAGI114641932KIRCDifferentially expressed in tumor samples compared to normal samples.
SMGs within edgetic gains or lossesPIK3CA26233890KIRCThe PI3K/AKT pathway is modestly mutated but highly activated in RCC; representing a promising drug target.
SMGs within edgetic gains or lossesRNF228827316KIRCRNF20 was demonstrated to have tumor suppressor activity in KIRC.
SMGs within edgetic gains or lossesTP5328551630KIRCImmunoreactivity for TP53 was elevated in cancer cells when compared to unchanged kidney;
SMGs within edgetic gains or lossesVHL27530247KIRCVHL missense mutations associated with KIRC.

To download a file, either filter the gene of interest or select all the entries and then press the "Download as Excel table" button